Safety of dermatologic medications in pregnancy and lactation: An update - Part I: Pregnancy.

Autor: McMullan P; Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut., Yaghi M; Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida., Truong TM; School of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey; Center for Dermatology, Rutgers Robert Wood Johnson Medical School, Somerset, New Jersey., Rothe M; Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut., Murase J; Department of Dermatology, University of California, San Francisco, California; Palo Alto Foundation Medical Group, Mountain View, California., Grant-Kels JM; Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut; Department of Dermatology, University of Florida, Gainesville, Florida. Electronic address: grant@uchc.edu.
Jazyk: angličtina
Zdroj: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Oct; Vol. 91 (4), pp. 619-648. Date of Electronic Publication: 2024 Jan 26.
DOI: 10.1016/j.jaad.2023.10.072
Abstrakt: The breadth of therapeutic options for the management of dermatologic skin conditions continues to expand rapidly as exemplified by biologics and small molecule drug development. While dermatologists and health care providers are aware of the underlying mechanisms and indications for these therapeutics, there is a recognized practice gap due to an incomplete understanding of the safety of these medications in women of childbearing age during the prepartum, antepartum, and postpartum phases. Although a two-part continuing medical education review was published regarding the prescribing practices and safety profiles of these new therapeutics in women of childbearing age while pregnant or lactating in 2014, many new medications have been approved since then. Herein, we will update the safety of dermatologic therapies during pregnancy and Part II will review the safety of medications during lactation.
Competing Interests: Conflicts of interest Dr Rothe is a stockholder in the following companies: Eli Lilly and Co, Merck and Co, GE Healthcare, Organon and Co, and Pfizer Inc. Drs McMullan, Yaghi, Truong, Murase, and Grant-Kels have no conflicts to declare.
(Copyright © 2024 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: